Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug;52(4):247-253.
doi: 10.1007/s13139-018-0522-0. Epub 2018 May 2.

Factors Associated with Dose Determination of Radioactive Iodine Therapy for Differentiated Thyroid Cancer

Chae Moon Hong  1   2 , Byeong-Cheol Ahn  1   2
Affiliations
Review

Factors Associated with Dose Determination of Radioactive Iodine Therapy for Differentiated Thyroid Cancer

Chae Moon Hong et al. Nucl Med Mol Imaging. 2018 Aug.

Abstract

Radioactive iodine (RAI) therapy for differentiated thyroid cancer has been successfully used for more than 70 years. However, there is still plenty of controversy surrounding the use and doses of radioiodine. There is insufficient evidence to answer the questions. Recent American Thyroid Association (ATA) guidelines seem to favor low-dose RAI, based on recent clinical trials and meta-analyses. However, long-term follow-up data remains limited, and there are additional factors we should consider that might affect the efficacy of RAI therapy. Therefore, until sufficient data are available, it is necessary to remain cautious about determining RAI doses by considering multiple patient-specific variables.

Keywords: Differentiated thyroid cancer; High dose; I-131; Low dose; Radioactive iodine.

PubMed Disclaimer

Conflict of interest statement

Compliance with Ethical StandardsChae Moon Hong and Byeong-Cheol Ahn declare that they have no conflict of interest.This article does not contain any studies with animals or human participants performed by any of the authors.None.

References

    1. La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer. 2015;136:2187–2195. doi: 10.1002/ijc.29251. - DOI - PubMed
    1. Verburg FA, Mäder U, Reiners C, Hänscheid H. Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical 131I therapy in both high- and low-risk patients. J Clin Endocrinol Metab. 2014;99:4487–4496. doi: 10.1210/jc.2014-1631. - DOI - PubMed
    1. Hong CM, Ahn B-C. Redifferentiation of radioiodine refractory differentiated thyroid cancer for reapplication of I-131 therapy. Front Endocrinol. 2017;8:260. doi: 10.3389/fendo.2017.00260. - DOI - PMC - PubMed
    1. Verburg FA, Hänscheid H, Luster M. Radioactive iodine (RAI) therapy for metastatic differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab. 2017;31:279–290. doi: 10.1016/j.beem.2017.04.010. - DOI - PubMed
    1. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid Cancer. Thyroid. 2016;26:1–133. doi: 10.1089/thy.2015.0020. - DOI - PMC - PubMed

LinkOut - more resources